These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3207893)

  • 1. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
    Fridrik MA; Wahl G; Herbinger W
    Blut; 1988 Dec; 57(6):357-60. PubMed ID: 3207893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
    Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection].
    Wataya S; Sudou H; Sakamaki I; Wano Y; Ueda T; Nakamura T
    Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):438-41. PubMed ID: 7563939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose Ara-C for patients with myelodysplastic syndromes.
    Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
    Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
    Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of RAEB-t with intensive chemotherapy and GM-CSF.
    Brito-Babapulle F; Lord JA; Whitmore DN
    Leuk Res; 1989; 13(7):605-7. PubMed ID: 2668647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
    Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
    Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia.
    Shtalrid M; Lotem J; Sachs L; Berrebi A
    Eur J Haematol; 1987 Jan; 38(1):3-11. PubMed ID: 3472902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 14. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
    J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
    Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.